



BioPharmica manages a strong portfolio of biomedical technologies emerging from research by leading Universities, Medical Institutes and Hospitals across Australia.

One of the investments is Diagnostic Array Systems which holds the BacTrak System Technology.



Australian Research Network

The Australian Research Network represents BioPharmica Limited.

The Australian Research Network is a technology transfer company based in Los Angeles focused on the commercialization of early stage technologies from Australia.

The Australian Research Network is a wholly owned subsidiary of TM Ventures Pty Ltd, a business development company based in Sydney Australia.

Summary of the Opportunity

An exciting opportunity exists for a diagnostic company to license the BacTrak technology in the field of respiratory infection diagnosis. The BacTrak System is a diagnostic test for the detection of multiple bacteria in single sputum sample (e.g. diagnosis of pneumonia). The system is a PCR/microarray based system which is a faster system compared to conventional microbiological systems.

Technology

Our product, identifies the cause of disease in sputum samples quickly, efficiently and accurately. The success rate will be more than 90% as opposed to the current 20%. Furthermore the results generated with our technology are obtained within 5 hours whereas the method currently available requires several days for bacterial recognition. The short diagnosis time means patients can receive appropriate medication within a day after visiting their GP or specialist.

Features

Conventional Method

- Not automated
- Requires 2-3 days or several weeks for some bacteria
- Single test at a time
- Uncertain results
- Success rate 20%
- Requires bacterial targeting
- Disposal of tests require additional safety procedures as bacteria remain infective


BacTrak Method

- Most of the procedure automated
- Requires only 5 hours for all bacteria
- Multiple tests done simultaneously
- Accurate results
- Success rate 90-100%
- Does not require bacterial targeting
- Disposal of tests does not require additional safety procedures as no live organisms used

BacTrak Data

- Assay validated for 16 pathogens
- SOP's in place
- Software in development
- *Tuf* gene exemplified as gene of choice
- Success rate 90-100%

BacTrak Process



Intellectual Property

The IP (PCT WO 2007/012131 A1) relates generally to a method of identifying micro-organisms in a sample using a *tuf* gene variable region. Therefore only one PCR is required for all pathogens.

Opportunity

The technology and methodology described in the patent is available for licensing.

For Further Information

Tony Romagnino
Managing Director
Australian Research Network
T 1-310-425-2990
tromagnino@australianresearchnetwork.com
www.australianresearchnetwork.com

David Breeze
Chairman
BioPharmica Limited
T +61 8 9328 8366
david@biopharmica.com.au
www.biopharmica.com.au

